Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: Results from the open-label, randomised, phase II FRACTION-RCC trial

Authors

T K Choueiri, Harvard University
R K Pachynski, Washington University School of Medicine in St. Louis
et al.

Journal

ESMO Open

Publication Date

12-1-2024

Volume

9

Issue

12

First Page

104073

Document Type

Open Access Publication

DOI

10.1016/j.esmoop.2024.104073

Rights and Permissions

Choueiri TK, Kuzel TM, Tykodi SS, Verzoni E, Kluger H, Nair S, Perets R, George S, Gurney H, Pachynski RK, Folefac E, Castonguay V, Lee CH, Vaishampayan U, Miller WH Jr, Bhagavatheeswaran P, Wang Y, Gupta S, DeSilva H, Lee CW, Escudier B, Motzer RJ. Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial. ESMO Open. 2024 Dec;9(12):104073. doi: 10.1016/j.esmoop.2024.104073. © 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Choueiri, T K; Pachynski, R K; and et al., "Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: Results from the open-label, randomised, phase II FRACTION-RCC trial." ESMO Open. 9, 12. 104073 (2024).
https://digitalcommons.wustl.edu/oa_4/5268

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.